We recently showed that the human telomerase reverse transcriptase (hTERT) 
Introduction
Apoptosis is a programmed cell death process involved in normal development and homeostasis of multicellular organisms. Disruption of the normal apoptotic pathway has been implicated in many human diseases, including cancer. 1 Cancer gene therapies using proapoptotic genes to force cancer cells through the apoptotic pathway have been tested extensively. These genes include p53, 2 Fas ligand, 3 Bak, 4 Bax 5 and caspase-8. 6 While p53 gene therapy showed promise clinically in the treatment of cancers and is relatively safe to normal cells, other genes may be needed when p53-resistant tumors are present. For example, Bax can kill both p53-sensitive and p53-resistant cancer cells both in vitro and in vivo. 5 However, most of these proapoptotic genes, although very strong in terms of cytotoxicity, are still limited to laboratory research and have not yet entered into clinical trials. One of the concerns is their toxicity to normal cells, since these proapoptotic genes are not selective and can kill both cancer cells and normal cells.
To prevent the toxicity of proapoptotic genes in normal cells, targeted expression of desired therapeutic proteins within the tumor mass is desired. Targeted gene transfer may greatly increase the number of proteins that can be used for anticancer treatment, since many proteins that otherwise have too many undesirable adverse effects might then be used to treat cancer. Tissue-or cell-specific promoters represent one of the main methods of gene targeting. Several promoters have been identified and exploited to target transgene expression. [7] [8] [9] [10] However, most of these promoters are much weaker than commonly used viral promoters such as cytomegalovirus (CMV) early promoter and SV40 early promoter. In addition, most of these promoters are limited to certain types of tumor and cannot be used broadly in tumors of different origins. The marked heterogeneity of tumor origins has rendered a universal tumor-specific promoter elusive for a long time.
We and others recently demonstrated that the human telomerase reverse transcriptase (hTERT) promoter is useful for targeted transgene expression in human cancer cells. 11, 12 hTERT is the catalytic subunit of human telomerase and is highly active in immortalized cell lines and over 85% of human cancers, but inactive in most somatic cells. 13, 14 In adenovirus-mediated transgene experiments, we demonstrated that the hTERT promoter has high transcriptional activity in a variety of human cancer cell lines, but not in normal human cells. The hTERT promoter can drive tumor-specific Bax gene expression, induce tumorspecific apoptosis in human cancer cells in vitro, suppress xenograft tumor growth in nude mice, and prevent shortterm systemic toxicity. 11 The transcriptional activity of the hTERT promoter in syngenic mouse tumors and the potential stem cellrelated toxicity of the hTERT promoter-driven Bax gene are still unknown. To address these questions, we further tested the feasibility of using the hTERT promoter in targeted cancer gene therapy by using a syngenic mouse tumor model. We also determined the relative activity of hTERT promoter in human CD34
+ progenitor cells and the potential short-term and long-term toxic effects of hTERT promoter-mediated Bax gene expression in vivo.
Results
Transgene expression driven by the hTERT promoter in murine cell lines hTERT promoter activity was assessed in cultured murine fibrosarcoma UV-2237m cells, Lewis Lung carcinoma (LLC) cells, M109 lung carcinoma cells, LM2 cells, NIH3T3 cells, and normal mouse fibroblast (NMFB) cells by infecting the cells with Ad/hTERT-LacZ as described in Materials and methods. Ad/CMV-LacZ was used as the positive control and Ad/CMV-GFP as the negative control. Expression of bacterial ␤-galactosidase was analyzed 24 h after infection by either X-gal staining or enzyme assay as described in Materials and methods. In all the tumor cells, both the CMV and hTERT promoters drove strong ␤-galactosidase expression as shown by Xgal staining, while in NIH3T3 and NMFB cells, only infection with Ad/CMV-LacZ produced high levels of transgene expression (Figure 1a ). CMV and hTERT promoter activity differed by only three-to 10-fold in tumor cells compared with about 150-fold in NMFB cells ( Figure  1b) . It is noteworthy that in LM2 cell, a transformed murine lung epithelial cell line derived from a papillary tumor, 15 CMV and hTERT promoter activity differed by 21-fold; whereas in NIH3T3 cell, a non-transformed special 'normal' mouse fibroblastic cell line capable of indefinite growth, CMV and hTERT promoter activity differed by more than 80-fold. These results are in line with those obtained in human cancer cell lines and normal cells, 11 demonstrating that the hTERT promoter can efficiently use mouse transcription machinery and that hTERT promoter is highly active in murine tumor cells and transformed cells, but relatively quiescent in normal cells.
hTERT promoter-driven Bax gene expression suppresses tumor cells in vitro
We recently developed a binary adenoviral vector system that enables us to overcome the difficulties in constructing adenoviral vectors expressing high levels of the strongly apoptotic Bax gene. 16 In brief, the system contains two adenoviral vectors. One of these vectors contains human Bax cDNA under the control of a minimal synthetic promoter comprising five Gal4-binding sites and a TATA box, which is dormant in 293 packaging cells, thus avoiding the toxic effects of the Bax gene on 293 cells and allowing vector (Ad/GT-Bax) production. Expression of the Bax gene can be induced by co-infecting the Ad/GT-Bax virus with another adenoviral vector that expresses a synthetic transactivator consisting of a fusion protein comprising a Gal4 DNA-binding domain and a VP16 activation domain. Administration of this binary vector system to cancer cells elicited extensive apoptosis in vitro and suppressed tumor growth in vivo. 5 The toxicity of the Bax gene in normal cells was prevented by using the hTERT promoter to drive tumor-specific Bax gene expression in human cancer cells.
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To test whether the hTERT promoter can similarly drive Bax gene expression in murine tumor cells, the effects of Bax gene expression induced by the hTERT pro-Gene Therapy moter were compared with that induced by the PGK promoter, a constitutive promoter from mouse housekeeping gene 3-phosphoglycerate kinase. We first used the XTT assay to compare cell viability after treating UV-2237m cells, LLC cells and M109 cells with PBS, Ad/CMV-GFP + Ad/PGK-GV16, Ad/GT-Bax + Ad/CMV-GFP, Ad/GTBax + Ad/hTERT-GV16, or Ad/GT-Bax + Ad/PGK-GV16 (Figure 2a) . Treatment with either Ad/GT-Bax + Ad/PGK-GV16 or Ad/GT-Bax + Ad/hTERT-GV16 had comparable cell-killing effects on these tumor cells, while all the control treatments had minimal effects on cell viability. The results demonstrate that the hTERT promoter can drive Bax gene expression in murine tumor cells and suppress tumor cell growth in vitro.
To confirm that the growth suppression caused by Bax 
b) Flow cytometric analysis of apoptotic (sub-G1) cells on UV2237m cells. Treatments are at the top of panels, and apoptotic cell percentages underneath each panel. (c) Induction of Bax gene expression in UV-2237m cells. Western blot analysis was performed 48 h after treatments with PBS (lane 1), Ad/GT-Bax + Ad/CMV-GFP (lane 2), Ad/GT-Bax + Ad/PGK-GV16 (lane 3) and Ad/GT-Bax + Ad/hTERT-GV16 (lane 4). The relative Bax:␤-actin was listed under each lane with the PBS-treated cells normalized to 1.
expression was due to apoptosis rather than growth inhibition, fluorescence-activated cell sorter (FACS) analysis was used. UV2237m cells were treated with binary vectors and cells were harvested 48 or 72 h after the treatment and subjected to FACS analysis to determine the fraction of apoptotic cells by quantifying the sub-G1 population ( Figure 2b ). The Ad/GT-Bax + Ad/hTERT-GV16 and Ad/GT-Bax + Ad/PGK-GV16 treatments resulted in comparable apoptosis populations, suggesting that the hTERT promoter is as strong as the PGK promoter in inducing Bax gene expression and apoptosis in murine tumor cells. Expression of the Bax gene in UV2237m cells treated by Ad/GT-Bax + Ad/hTERT-GV16 or Ad/GT-Bax + Ad/PGK-GV16 were confirmed by Western analysis (Figure 2c ). Both hTERT promoter and PGK promoter induced very high expression of Bax gene in UV-2237m cells, whereas there were minimal Bax expression in control cells.
hTERT promoter drives tumor-specific Bax gene expression in vivo and suppresses syngenic tumor growth
To further evaluate the feasibility of using the hTERT promoter for in vivo Bax gene therapy in syngenic tumors, we established UV-2237m tumors subcutaneously in immune-competent C3H mice and treated the tumors with hTERT or PGK promoter-driven Bax gene vectors. After three sequential intratumoral injections of the vectors, tumor size changes were monitored for 3 weeks, by which time the mice in control groups had to be killed according to our institutional policy because the tumor sizes reached 15 mm in diameter. Treatment with Ad/GT-Bax + Ad/hTERT-GV16 or Ad/GT-Bax + Ad/PGK-GV16 resulted in the same level of tumor growth suppression, which was significantly different from the changes resulting from treatments with PBS, Ad/E1 Ϫ , or Ad/GT-LacZ + Ad/PGK-GV16 (Figure 3a ). The group treated with Ad/GT-LacZ + Ad/PGK-GV16 also showed mild inhibition of tumor growth, probably due to the immune response in C3H mice. 17 Expression of the Bax gene in tumors was confirmed by immunohistochemical staining (Figure 3b ). Intratumoral injection of either Ad/GT-Bax + Ad/hTERT-GV16 or Ad/GT-Bax + Ad/PGK-GV16 binary vector resulted in strong Bax gene expression in UV-2237m tumors. In comparison, when the binary vectors were systemically injected through the tail veins of mice, only the PGK promoter induced strong Bax expression in the liver, while the hTERT promoter did not induce detectable Bax expression. These results demonstrate that the hTERT promoter is highly active in murine tumors, but quiescent in normal liver in vivo and that it effectively drives tumor-specific Bax gene expression in vivo and suppresses syngenic tumor growth.
hTERT promoter prevents acute liver toxicity of Bax gene with no obvious long-term toxicity
To test the potential toxicity of systemic delivery of the Bax gene in mice, adult BALB/c mice in groups of 10 were infused via the tail vein with PBS, Ad/GT-Bax + Ad/CMV-GFP, Ad/GT-Bax + Ad/hTERT-GV16, or Ad/GT-Bax + Ad/PGK-GV16 at a dose of 6 × 10 10 viral particles/mouse, three times within 1 week. The mice were monitored for up to 6 months. Blood samples were collected at 2 days, 10 days, 30 days, 100 days and 6 months after the last injection to determine the hemogram and serum levels of AST and ALT. The most significant toxic effects occurred in the group treated with Ad/GT-Bax + Ad/PGK-GV16: within 1 week of viral injections, six out of the 10 mice died of acute liver toxicity (P Ͻ 0.01). The remaining four in the group recovered and survived the 6-month experiment. In contrast, none of the mice in the Ad/GT-Bax + Ad/hTERT-GV16 group or the other control groups died during the experiment. In all of the mice that finished the experiment, none had significant differences in hemoglobin level or white blood cell (WBC) or red blood cell (RBC) counts, suggesting that the bone marrow toxicity of the adenovirusmediated Bax gene is minimal ( Table 1) . As we reported previously, 11 AST and ALT levels were significantly Gene Therapy higher (P р 0.001) only in the Ad/GT-Bax + Ad/PGK-GV16 group 2 days after viral injection than in all other groups, indicating acute liver toxicity caused by Bax expression. From day 10 and thereafter, no significant differences in AST or ALT were seen in any of the groups (Table 2) . Together, these results suggest that the hTERT promoter can be used to prevent the acute liver toxicity of proapoptotic genes systemically while having no obvious long-term toxic effects.
Minimal hTERT activity in hematopoietic CD34
+ progenitor cells One of the major concerns about the use of the hTERT promoter to drive expression of proapoptotic or cytotoxic genes is its potential toxicity to stem cells. To test whether hTERT is active in progenitor stem cells, we isolated normal human bone marrow CD34
+ hematopoietic progenitor cells and compared the ␤-galactosidase activity of 20 Indeed, when we combined Superfect with Ad/CMV-GFP, the fluorescent (ie infected) population of CD34 + cells reached 60% at MOI of 10 000 (data not shown). When we infected human CD34 + progenitor cells with Ad/hTERTLacZ or Ad/CMV-LacZ under similar conditions, the difference in ␤-galactosidase activity was more than 100-fold (Figure 4) , which is similar to that in other normal cells (Figure 1b) . 11 Moreover, hTERT promoter activity was very close to basal levels, indicating hTERT promoter activity is very low in these CD34
+ progenitor cells. The low transcriptional activity of the hTERT promoter in human progenitor cells and the lack of detectable changes in blood cell profiles in our long-term in vivo study suggest that the potential stem cell-related toxicity of adenovirus-mediated, hTERT-driven proapoptotic gene expression, if any, would be limited. 
Discussion
We reported previously that the hTERT promoter can induce tumor-specific Bax gene expression in human cancer cell lines and can suppress xenograft tumor growth in nude mice. Transgene expression from hTERT promoter after adenovirus-mediated systemic gene delivery was not detected in all the adult mice organs studied.
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Yet whether the hTERT promoter can actually use mouse transcription machinery was not clear until this study. The mouse TERT (mTERT) promoter has been cloned and the homology between the hTERT and mTERT core promoter regions is about 50%, with one important E-box absent in the mTERT promoter. 21 At least some of the regulatory mechanisms in the hTERT and mTERT promoters are distinct. Yin et al 22 recently showed that NF-B binds and activates the mTERT promoter, but not the hTERT promoter. We have shown here that, despite the apparent distinct regulatory mechanisms, the hTERT promoter can efficiently use mouse transcription machinery. The hTERT promoter is highly active in murine tumor cells, but quiescent in normal murine cells and tissues, further demonstrating that it is highly tumor-specific. It induces tumor-specific Bax gene expression and suppresses syngenic tumor growth. It can also prevent the liver toxicity of proapoptotic gene expression without compromising its antitumor activity. These data demonstrate that the hTERT promoter should be useful for targeting the pharmaceutical effects of a therapeutic gene to cancer cells. Indeed, the fact that telomerase is active in various tumor types and in over 85% of all primary tumors suggests that the hTERT promoter will find broad applications in cancer gene therapy.
The mechanisms by which the short hTERT core promoter acts so differently in tumor and normal cells are still largely unknown. However, the widespread expression of hTERT in heterogeneous tumors suggests that general transcriptional factors, rather than any specific transcriptional factors, are responsible for the upregulation of hTERT in tumor cells. In fact, it has been shown that retroviral expression of c-Myc, an E-Box binding protein, increases the amount of hTERT mRNA and activates telomerase in normal human epithelial cells and fibroblasts, 23 and several reports point to the direct activation of TERT transcription by c-Myc. [23] [24] [25] Another report suggests that c-Myc and Sp1 cooperatively determine hTERT expression. 26 However, this limited known number of general cis-and trans-elements apparently cannot account for all of hTERT's high levels of activity in cancer cells. Novel cis-elements and corresponding transcription factors may exist. Indeed, a recent report 27 identified a novel transcription factor-binding element named MT-box, which is conserved between the human and mouse TERT promoters. Characterization of any novel transcription factors and transcription factor-binding sites will provide new insights on the mechanism of hTERT activation in cancer cells. On the other hand, the possibility that active repression mechanisms exist in normal cells cannot be ruled out.
Stem cells are capable of self-renewal and have telomerase activity detectable by sensitive assays. 28, 29 Potential toxicity to stem cells has become one of the major concerns about use of the hTERT promoter to drive proapoptotic or cytotoxic gene expression. In our long-term toxicity experiment in mice, repeated tail vein injection Gene Therapy of high-dose binary adenoviral vectors expressing the Bax gene from the hTERT promoter did not produce detectable effects on blood cell counts, suggesting that a hTERT-Bax construct delivered by adenovirus would have minimal toxicity on hematopoietic stem cells. Since blood cell profiles in animals that survived Ad/PGK-GV16 + Ad/GT-Bax were also normal, the minimal bone marrow toxicity may be explained by the ineffectiveness of the adenovirus in transducing stem cells. We have found that without the help of Superfect, adenoviral vectors infect leukemia cells or bone marrow cells poorly (data not shown). This observation is consistent with a report that even a very high dose of an adenoviral vector and prolonged cell-vector contact can infect only a limited percentage of stem cells. 18, 19 Nevertheless, in the presence of Superfect and a very high dosage of virus (10 000 MOI), when fluorescent (ie infected) population can reach 60% by Ad/GFP infection (data not shown), transgene expression from the hTERT promoter in human CD34
+ hematopoietic progenitor cells was more than 100-fold lower than that from the CMV promoter, similar to that observed in NMFB (Figure 1b) and normal human cells. 11 This result suggests that, at least in CD34
+ hematopoietic progenitor cells enriched in stem cells, the hTERT promoter is much less active than in cancer cells, which is also consistent with another report that normal human myeloid progenitor cells (CD34
) had barely detectable telomerase activity, while leukemia cells had high telomerase activity. 30 Nevertheless, the effect of hTERT promoter-mediated proapoptotic gene expression on human stem cells needs further investigation when sufficient pure human stem cells are available. On the other hand, there are some other stem cells which are high in telomerase activity, such as intestinal crypt stem cells, which may become other origins of toxicity when hTERT promoter-driven toxic genes are expressed. However, our previous data showed that when Ad/CMV-LacZ was injected through the tail vein, only liver and spleen showed dramatic increases in ␤-galactosidase activity, 11 suggesting that adenovirus fails to reach other organs and the toxicity of systemically delivered adenovirus to other stem cells would be limited. In conclusion, the difference in hTERT promoter activities between tumor cells and progenitor cells could provide a 'window' that allows the use of proapoptotic genes for cancer treatment without significant toxicity to stem cells. Furthermore, if the hTERT promoter is used in the context of vectors that transduce stem cells poorly, such as adenovirus, the toxicity of hTERT promotermediated proapoptotic gene expression in stem cells would be minimal.
Materials and methods

Recombinant adenoviral vectors Vectors Ad/E1
Ϫ , Ad/hTERT-LacZ, Ad/CMV-LacZ, Ad/GT-LacZ, Ad/GT-Bax, Ad/PGK-GV16, Ad/CMV-GFP and Ad/hTERT-GV16 have been described previously. 11, 16 Recombinant virus from a single plaque was expanded in 293 cells and twice purified by ultracentrifugation on a cesium chloride gradient. Viral titers were determined by optical absorbance at A 260 (OD 260 , 1 A 260 unit = 10 12 particles/ml) and by plaque assay. Titers determined by OD 260 (ie viral particles) were used in all the experiments, while titers determined by plaque assay were used only as additional information. Particle/plaque ratios normally fell between 50:1 and 100:1. All viral preparations were free of contamination by E1
+ adenovirus and endotoxin.
Analysis of in vitro gene expression
Mouse UV-2237m fibrosarcoma cells were obtained from Dr I Fidler of our institution. Normal mouse fibroblast (NMFB) cells were isolated from the pancreases of Balb/c mice using conventional techniques. Lewis lung carcinoma cells, M109 lung carcinoma cells, LM2 lung epithelial cells, and NIH3T3 cells were maintained in our laboratory. Normal human bone marrow CD34 + progenitor cells were separated by magnetic cell sorting (MACS) as described previously. 31 Cells were plated 1 day before vector infection at densities of 1 × 10 5 /well in 24-well plates. Cells were then infected with adenoviral vectors at multiplicities of infection (MOI) of 3000 viral particles/cell for UV-2237m, LLC, M109 and NMFB cells, 6000 viral particles/cell for NIH3T3 cells, and 10 000 viral particles/cell for LM2 and human CD34
+ bone marrow stem cells. The optimal MOI of viral infection in each cell line was predetermined by which over 60% of cells were infected. To achieve this high efficiency of adenovirus infection, Superfect was used in combination with adenovirus in LLC, M109, NIH3T3 and CD34
+ cells as described. 20 Twenty-four hours after infection, cells were either stained with X-gal to visualize ␤-galactosidase expression or harvested for biochemical analysis of ␤-galactosidase activity.
Histochemical studies
For X-gal staining, 8-m frozen sections were fixed with 50% ethanol and 50% methanol for 20 min at -20°C. The fixed sections were then stained with a solution containing 5 mm K 4 Fe(CN) 6 , 5 mm K 3 Fe(CN) 6 , 2 mm MgCl 2 , and 1 mg/ml X-gal at 37°C overnight. For immunohistochemical analysis of the Bax protein, tumors or livers were fixed in 10% formalin, embedded in paraffin, and then cut into 4-m sections. To retrieve antigens, the sections were baked, deparaffinized, and heated in citrate buffer (10 mm citric acid, pH 6.0) in a steamer. After endogenous peroxidase was inactivated by a 10-min exposure to 1.5% H 2 O 2 /methanol, the sections were incubated with blocking serum (goat serum) at room temperature for 30 min, rabbit anti-Bax polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h, and biotinylated goat anti-rabbit IgG antibody for 30 min. The specific binding of anti-Bax antibody was visualized with an avidin-biotin-peroxidase reagent (Vector Laboratories, Burlingame, CA, USA) and its substrate diaminobenzidine tetrachloride (Sigma, St Louis, MO, USA) and by counterstaining with Mayer's hematoxylin.
Biochemical analysis
Cultured cells were lysed in ␤-galactosidase assay buffer or protein extraction buffer. Cell debris was removed by microcentrifugation. Protein concentrations were determined using a kit from Pierce according to the manufacturer's instructions (Pierce, Rockford, IL, USA). ␤-Galactosidase activities were determined using a luminometer and a Galacto-Light Chemiluminescent Assay kit from Tropix (Bedford, MA, USA). Western analysis for Bax expression was performed as described previously. 16 Cell viability assay Cells were plated on 96-well plates at 1 × 10 4 per well 1 day before virus infection. Cells were then infected with adenoviral vectors at a total MOI of 4500 viral particles/cell. Cells were divided into four groups according to the viral vector system given: Ad/CMV-GFP + Ad/PGK-GV16, Ad/GT-Bax + Ad/CMV-GFP, Ad/GT-Bax + Ad/hTERT-GV16, or Ad/GT-Bax + Ad/PGK-GV16. In each group, the ratio of the two viral vectors was 2:1, a ratio shown to be optimal for the induction of transgene expression in preliminary experiments. 16 Phosphate-buffered saline (PBS) was used for mock infection. Cell viability was determined by XTT assay using a Cell Proliferation Kit II (Roche Molecular Biochemicals, Indianapolis, IN, USA) according to the manufacturer's protocol. In each treatment group, quadruplicate wells were measured for cell viability at 24, 48 and 72 h after infection. These experiments were performed at least twice for each cell line.
Apoptosis analysis by flow cytometry
Mouse cells were plated at densities of 1 × 10 6 /100-mm plate 1 day before infection. The cells were then infected with recombinant adenoviral vectors at an MOI of 4500 viral particles/cell. Forty-eight hours later, both adherent and floating cells were harvested by trypsinization, washed with PBS, and fixed in 70% ethanol overnight. Cells were then stained with propidium iodide (PI) for analysis of DNA content. Apoptotic cells were quantified by flow cytometric analysis performed in the Flow Cytometry Core Laboratory at our institution.
Animal experiments
All mice were cared for according to the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication number 85-23) and the institutional guidelines of The University of Texas MD Anderson Cancer Center. In vivo infusion of adenoviral vectors into and subsequent tissue removal from BALB/c mice were done as described previously. 11 For the subcutaneous tumor model, 5 × 10 6 UV-2237m cells were inoculated subcutaneously into the dorsal flank of 6-to 8-week-old C3H mice (National Cancer Institute) to establish tumors. After tumors reached approximately 5 mm in diameter, mice were given three sequential intratumoral injections of 9 × 10 10 viral particles in a volume of 100 l per dose. Tumor sizes were measured three times a week. Tumor volumes were calculated using the formula a × b 2 × 0.5, where a and b represent the larger and smaller diameters, respectively.
Analysis of serum AST and ALT
Blood was drawn from the tail vein of mice 48 h after adenovirus infusion. The levels of serum aspartate transaminase (AST) and alanine transaminase (ALT) were measured as described. 5 
Statistical analysis
Differences among the treatment groups were assessed by analysis of variance (ANOVA) using statistical software (StatSoft, Tulsa, OK, USA). For the experiments of tumor growth in vivo, ANOVA with a repeated measurement model was used. A P value р0.05 was considered significant.
